VILDAPRIDE M 1000 TAB

About

VILDAPRIDE M 1000 TAB is a combination medication designed for the effective management of type 2 diabetes mellitus. It combines Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Metformin, a biguanide. Vildagliptin enhances the body's natural ability to regulate blood glucose by increasing the levels of active incretin hormones, which promote glucose-dependent insulin secretion and suppress glucagon release. Metformin primarily acts by reducing glucose production in the liver, decreasing glucose absorption from the intestines, and improving insulin sensitivity in peripheral tissues. This synergistic action addresses multiple pathophysiological defects in type 2 diabetes, leading to significant improvements in both fasting and post-meal blood glucose levels.

Uses

• Treatment of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• When monotherapy with Metformin or Vildagliptin is insufficient.
• To improve glycemic control in adults.

Directions For Use

Take orally, usually with meals to minimize gastrointestinal upset. Follow your doctor's prescribed dosage and schedule strictly.

Benefits

• Improved HbA1c levels.
• Dual mechanism of action for comprehensive control.
• Reduced fasting and post-prandial glucose.
• Potential for weight neutrality or modest weight loss.
• Lower risk of hypoglycemia compared to sulfonylureas.
• Convenient combination therapy.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Metallic taste
• Headache
• Dizziness
• Nasopharyngitis
• Joint pain
• Skin rash
• Fatigue
• Lactic acidosis (rare but serious)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption due to increased risk of lactic acidosis, especially with Metformin.
• Pregnancy - Generally not recommended during pregnancy; consult a doctor. Use only if potential benefits outweigh risks.
• Breastfeeding - Not recommended as components may pass into breast milk. Consult a healthcare professional.
• Liver - Use with caution; Metformin is contraindicated in severe hepatic impairment. Vildagliptin may require dose adjustment.
• Kidney - Metformin is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Vildagliptin requires dose adjustment based on renal function.
• Lung - Severe respiratory insufficiency can increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.